BLAC vs. CNDA, RACY, AXAC, IVCB, MEAC, KVAC, GHIX, SEDA, MCAA, and BRKH
Should you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Concord Acquisition Corp II (CNDA), Relativity Acquisition (RACY), AXIOS Sustainable Growth Acquisition (AXAC), Investcorp Europe Acquisition Corp I (IVCB), SEP Acquisition (MEAC), Keen Vision Acquisition (KVAC), Gores Holdings IX (GHIX), SDCL EDGE Acquisition (SEDA), Mountain & Co. I Acquisition Corp. (MCAA), and Burtech Acquisition (BRKH). These companies are all part of the "holding & other investment offices" industry.
Concord Acquisition Corp II (NYSE:CNDA) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 0.2% of Concord Acquisition Corp II shares are held by insiders. Comparatively, 25.3% of Bellevue Life Sciences Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Concord Acquisition Corp II has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.
In the previous week, Bellevue Life Sciences Acquisition had 2 more articles in the media than Concord Acquisition Corp II. MarketBeat recorded 3 mentions for Bellevue Life Sciences Acquisition and 1 mentions for Concord Acquisition Corp II. Concord Acquisition Corp II's average media sentiment score of 1.56 beat Bellevue Life Sciences Acquisition's score of 1.00 indicating that Bellevue Life Sciences Acquisition is being referred to more favorably in the news media.
Concord Acquisition Corp II and Bellevue Life Sciences Acquisition both received 0 outperform votes by MarketBeat users.
Concord Acquisition Corp II's return on equity of 0.00% beat Bellevue Life Sciences Acquisition's return on equity.
Summary
Bellevue Life Sciences Acquisition beats Concord Acquisition Corp II on 5 of the 7 factors compared between the two stocks.
Get Bellevue Life Sciences Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellevue Life Sciences Acquisition Competitors List
Related Companies and Tools
